BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for ABBVIE · Biopharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · Senate · $80,000.00 income · posted Oct 16, 2025

Lobbying activity 2

Health Issues

Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues related to Medicare drug pricing and reimbursement DTC Advertising

Tariff (miscellaneous tariff bills)

Reciprocal tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.